Benign breast disease, mammographic breast density, and the risk of breast cancer. Read more about Benign breast disease, mammographic breast density, and the risk of breast cancer.
Clonal BRAF mutations in melanocytic nevi and initiating role of BRAF in melanocytic neoplasia. Read more about Clonal BRAF mutations in melanocytic nevi and initiating role of BRAF in melanocytic neoplasia.
A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. Read more about A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast.
Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy. Read more about Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy.
Screening outcomes in older US women undergoing multiple mammograms in community practice: does interval, age, or comorbidity score affect tumor characteristics or false positive rates? Read more about Screening outcomes in older US women undergoing multiple mammograms in community practice: does interval, age, or comorbidity score affect tumor characteristics or false positive rates?
Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. Read more about Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803.
When progressive disease does not mean treatment failure: reconsidering the criteria for progression. Read more about When progressive disease does not mean treatment failure: reconsidering the criteria for progression.
Relationship between mammographic density and breast cancer death in the Breast Cancer Surveillance Consortium. Read more about Relationship between mammographic density and breast cancer death in the Breast Cancer Surveillance Consortium.
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. Read more about Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.
